PKI 14-22 amide,myristoylated

Name: PKI 14-22 amide,myristoylated
Brand: MedChemExpress
SKU: HY-P1291
Rating: 5.0 (3 reviews)

Art. -Nr.: HY-P1291 Reinheit: 98.87%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

PKI 14-22 amide, myristoylated is a selective, cAMP-dependent, competitive PKA inhibitor with K_i=~36 nM. The myristoylation modification of PKI 14-22 amide, myristoylated makes it more permeable to cell membranes and blood-brain barriers than the precursor molecule. PKI 14-22 amide, myristoylated can block the phosphorylation of cAMP-dependent downstream targets (such as CREB). PKI 14-22 amide, myristoylated can prevent the development of morphine analgesic tolerance in mice, and also inhibits protein translation and negative-strand RNA synthesis of Zika virus. PKI 14-22 amide, myristoylated can be used in research fields such as opioid tolerance mechanisms and antiviral drugs.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Kundenspezifische Peptidsynthese

PKI 14-22 amide,myristoylated Chemische Struktur

CAS. Nr. : 201422-03-9

Größe	Verfügbarkeit	Menge
1 mg	Auf Lager	Estimated Time of Arrival: December 31
5 mg	Auf Lager	Estimated Time of Arrival: December 31
10 mg	Angebot einholen
50 mg	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 3 publication(s) in Google Scholar

Other Forms of PKI 14-22 amide,myristoylated:

PKI 14-22 amide,myristoylated TFA In-stock

3 Publications Citing Use of MCE PKI 14-22 amide,myristoylated

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle PKA Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen

PKA PKAR PKACα

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

IC₅₀ & Target

Zika virus

In Vitro

PKI 14-22 amide,myristoylated (20-40 μM; 72 h) significantly inhibits Zika virus replication in HUVEC and astrocytes, reducing viral titers by more than 85% without causing significant cytotoxicity^[2].
PKI 14-22 amide,myristoylated (10-40 μM; 4-24 h) inhibits viral structural protein (capsid/NS1) expression and positive and negative strand RNA synthesis^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[2]

Cell Line:	HUVEC
Concentration:	10 μM, 20 μM, 40 μM
Incubation Time:	48-72 h
Result:	Significantly reduced expression of viral capsid and NS1 proteins in a dose-dependent manner. At 40 μM, protein levels were undetectable by 72 hpi, while 10 μM showed partial inhibition.

In Vivo

PKI 14-22 amide, myristoylated (5 nmol/mouse; intracerebroventricular injection; 3 times: 1 time/1 hour before surgery + 2 times/24 and 48 hours after surgery) completely preventes the development of Morphine analgesic tolerance in the mouse morphine tolerance model, without affecting the withdrawal reaction induced by Naloxone (HY-17417A)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Swiss Webster mice (25-30 g, 6 weeks), morphine tolerance model via 75 mg pellet implantation^[3]
Dosage:	5 nmol/mouse
Administration:	1 dose (1 h before pellet implantation) + 2 additional doses at 24 h and 48 h post-implantation, total 3 doses over 3 days.
Result:	In the tail immersion test, morphine-pelleted mice pre-treated with PKI showed no tolerance to morphine’s antinociceptive effect, with ED₅₀ values comparable to naive mice (6.2 vs. 6.6 mg/kg, non-significant difference).

Molekulargewicht

1209.49

Formel

C₅₃H₁₀₀N₂₀O₁₂

CAS. Nr.

201422-03-9

Appearance

Solid

Color

White to off-white

Sequence Shortening

Myristoyl-GRTGRRNAI-NH2

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 50 mg/mL (41.34 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	0.8268 mL	4.1340 mL	8.2679 mL
5 mM	0.1654 mL	0.8268 mL	1.6536 mL
10 mM	0.0827 mL	0.4134 mL	0.8268 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Reinheit & Dokumentation

Purity: 98.96%

Select Batch:

Data Sheet (276 KB) SDS (394 KB)

COA (243 KB) RP-HPLC (264 KB) MS (73 KB) Elemental Analysis Report (102 KB)

Handling Instructions (2659 KB)

Verweise

[1]. L Ydrenius, et al. Activation of cAMP-dependent protein kinase is necessary for actin rearrangements in human neutrophils during phagocytosis. J Leukoc Biol. 2000 Apr;67(4):520-8. [Content Brief]

[2]. Cheng F, et al. Suppression of Zika Virus Infection and Replication in Endothelial Cells and Astrocytes by PKA Inhibitor PKI 14-22. J Virol. 2018 Jan 30;92(4):e02019-17. [Content Brief]

[3]. Gabra BH, et al. Pre-treatment with a PKC or PKA inhibitor prevents the development of morphine tolerance but not physical dependence in mice. Brain Res. 2008 Jun 27;1217:70-7. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	0.8268 mL	4.1340 mL	8.2679 mL	20.6699 mL
	5 mM	0.1654 mL	0.8268 mL	1.6536 mL	4.1340 mL
	10 mM	0.0827 mL	0.4134 mL	0.8268 mL	2.0670 mL
	15 mM	0.0551 mL	0.2756 mL	0.5512 mL	1.3780 mL
	20 mM	0.0413 mL	0.2067 mL	0.4134 mL	1.0335 mL
	25 mM	0.0331 mL	0.1654 mL	0.3307 mL	0.8268 mL
	30 mM	0.0276 mL	0.1378 mL	0.2756 mL	0.6890 mL
	40 mM	0.0207 mL	0.1033 mL	0.2067 mL	0.5167 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.